For years, the compliance line for small grantees was simple: if you had no contract pharmacies, manufacturer restrictions did not really touch you. That era is ending. A wave of "universal claims" mandates now pulls in-house and clinic-administered dispensing into scope. And many small entities are unprepared.
What changed
The original manufacturer restriction model, launched in 2021, targeted contract-pharmacy claims only, submitted through the 340B ESP platform. That kept the burden on entities with contract-pharmacy networks. Beginning in 2024 and accelerating through 2026, several major manufacturers expanded their demands to all 340B dispenses. Including drugs dispensed from an entity-owned pharmacy and drugs administered in the clinic (buy-and-bill).
Manufacturers now operating under a universal-claims posture include Lilly, Novo Nordisk, AstraZeneca, Bristol Myers Squibb, and Amgen. Because these companies produce insulins, GLP-1s, and other high-volume products, few grantees can avoid at least one of them.
Who is affected
The short answer is: nearly everyone, eventually. Specifically:
- Entities with no contract pharmacies that previously fell outside the model now have to submit data for in-house and clinic-administered claims.
- Small STD, Title X, and Ryan White clinics that dispense modest volumes are being asked for data they may never have compiled before.
- Multi-site entities face the burden across every registered site, multiplying the OPAIS and data-hygiene work.
The overall manufacturer-restriction count has grown to 42-plus manufacturers since 2021, and submission windows have standardized to 45 days. a hard deadline, not a suggestion.
The legal backdrop
Some states passed anti-restriction laws that carved out in-state entities, but those carve-outs are looking fragile. In April 2026, the Fourth Circuit struck down West Virginia's anti-restriction statute as likely preempted by federal law, signaling that state-level protections may not hold. Meanwhile, HRSA's voluntary rebate model. which would have shifted the mechanics again. was vacated by a federal court in February 2026, so the upfront-discount-plus-data model remains the reality for now.
What to do now
- Inventory every manufacturer you buy from and check each against the current restriction landscape. Our Manufacturer Policy Explorer filters this by entity type and dispensing model.
- Confirm your platform registrations in both 340B ESP and Truzo. Universal claims mean nothing if your submissions never arrive because you are not registered.
- Build a repeatable data-extraction process so 45-day windows are routine, not fire drills. This is a core piece of what program optimization and monthly internal audits maintain.
- Document eligibility rigorously. More data submitted means more surface area for a manufacturer or HRSA to question a claim. Clean patient-definition and eligibility records are your defense.
The bottom line
Universal claims mandates erase the old assumption that small, contract-pharmacy-free grantees are outside the manufacturer-restriction game. If you dispense any product from an affected manufacturer, you are in scope. The entities that stay whole will be the ones that treat data submission as a standing operational discipline. Not a scramble when a deadline lands.